• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Altitude Lab Startups Raise $154M in Capital

    2/18/25 11:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RXRX alert in real time by email

    SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse life science entrepreneurs in Utah by providing fully equipped laboratories, access to investors, business operations education, and a collaborative founder community.

    In addition, Altitude Lab awarded its inaugural Gibson Founder Fellowship to Carmen Kivisild, Ph.D., CEO and founder of Elnora AI. The fellowship provides early-career scientists with up to $150,000 in funding, scientific support, and mentorship to accelerate the growth of their startups.

    "Elnora AI is capturing real-world experimental data directly from academic researchers—positive, negative, and everything in between. This enables our AI-powered lab protocol optimizer, helping researchers get their experiments working faster while building the most comprehensive dataset for drug discovery," said Kivisild. "The Gibson Fellowship gave us critical funding and an anchor community as we relocated from Estonia to Utah. It's a once-in-a-lifetime opportunity to be mentored by Chris Gibson, Recursion's CEO and founder, while rapidly scaling Elnora at Altitude Lab."

    Applications for the 2025 Gibson Founder Fellowship are now open.

    "In 2025, we anticipate a wave of Series A funding rounds from our alumni and broader founder community," said Chandana Haque, executive director of Altitude Lab. "Our founders achieved major value inflection points in 2024, and we are thrilled to see them continue scaling."

    Key Milestones from Altitude Lab's Portfolio:

    • 19 startups in Altitude Lab's current cohort and 12 alumni
    • 70% of startups are led by at least one underrepresented founder
    • 90% of all participating startups have raised capital
    • Peel Therapeutics completed a Phase 1 trial for its PEEL-224 TOP1 inhibitor and closed the first tranche of its Series A
    • Rebel Medicine received IND approval for Alevatrix and closed the first tranche of its Series A
    • Sethera established Dr. Robert Langer, MIT faculty and co-founder of Moderna, as chair of their Scientific Advisory Board
    • Teiko launched a 25-marker spectral flow cytometry assay on fixed whole blood, combining high-throughput immune measurement of ~150 populations with extended stability for global clinical trials.

    Applications to join Altitude Lab's newest cohort are now open. Learn more and apply for residency and the Founder Fellowship at altitudelab.org.

    About Altitude Lab

    Altitude Lab is building a new, representative generation of founders to seed the next cycle of health care innovation in Utah's BioHive. Currently located in Gateway's BioHive Hub in Salt Lake City, Altitude Lab is an accelerator program focused on early stage life science and health care companies. The initiative is part of a larger city plan and collaborative vision from Recursion to foster socially-responsible entrepreneurship, job creation, and economic productivity. The Recursion Foundation, under which Altitude Lab operates, is a 501(c)(3) nonprofit organization.

    Learn more at altitudelab.org or connect on X.

    About Recursion

    Recursion (NASDAQ:RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

    Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at recursion.com, or connect on X (formerly Twitter) and LinkedIn.



    Media Contact
    Media@Recursion.com
    
    Investor Contact
    Investor@Recursion.com
    
    Get the next $RXRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RXRX

    DatePrice TargetRatingAnalyst
    12/17/2025$11.00Neutral → Overweight
    Analyst
    7/3/2025$5.00Equal-Weight
    Morgan Stanley
    5/22/2023$8.00Equal-Weight
    Morgan Stanley
    3/16/2023$17.00Buy
    Needham
    9/16/2022$20.00Overweight
    KeyBanc Capital Markets
    4/18/2022$10.00Buy → Neutral
    BofA Securities
    3/4/2022$32.00 → $10.00Outperform → Market Perform
    SVB Leerink
    12/8/2021$30.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $RXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Recursion to Participate in Upcoming Investor Conferences

    Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: 25th Annual Needham Virtual Healthcare Conference - Monday, April 13, 2026 Bank of America Health Care Conference 2026 - Tuesday, May 12, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.About RecursionRecursion (NASDAQ:RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational med

    4/7/26 8:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

    NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ:RXRX), a leading tech-bio company decoding biology through advanced data science and automation. Recursion's end-to-end platform is designed to connect discovery through development by integrating proprietary multimodal datasets, purpose-built AI models, and experimental biology. The addition of Citeline's real-world data and evidence capabilities strengthens this foundation, enabling more precise trial design, improved site selection, and faster, more informed development decisions

    3/31/26 9:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

    Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with p

    3/25/26 7:59:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dar Zavain

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    4/2/26 4:56:26 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Li Dean Y

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    4/2/26 4:56:19 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Gibson Christopher

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    3/25/26 4:36:02 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Recursion Pharmaceuticals Inc.

    SCHEDULE 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    3/27/26 11:36:08 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

    3/25/26 4:42:33 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Recursion Pharmaceuticals Inc.

    S-8 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

    2/25/26 6:47:42 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Recursion Pharmaceuticals upgraded by Analyst with a new price target

    Analyst upgraded Recursion Pharmaceuticals from Neutral to Overweight and set a new price target of $11.00

    12/17/25 8:47:25 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley resumed coverage on Recursion Pharmaceuticals with a new price target

    Morgan Stanley resumed coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $5.00

    7/3/25 7:50:07 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Recursion Pharmaceuticals with a new price target

    Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00

    5/22/23 7:50:41 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Leadership Updates

    Live Leadership Updates

    View All

    Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

    Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with p

    3/25/26 7:59:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

    Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board of Directors has unanimously approved a leadership transition plan to become effective January 1, 2026: Najat Khan, Ph.D., currently Chief R&D and Commercial Officer and a Board Member, will succeed Co-Founder and CEO Chris Gibson, Ph.D., as Chief Executive Officer and President. Najat will also continue in her role as a member of the Board of Directors.  Chris Gibson, Ph. D., current Co-Founder and CEO, will transition to Chairman of the Board of Directors and an interim Executive Adv

    11/5/25 6:28:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Financials

    Live finance-specific insights

    View All

    Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

    Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFm

    2/18/26 8:30:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

    Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 financial results on Wednesday, November 5, 2025, before the open of the financial markets.Recursion will host a (L)earnings Call on November 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6.About RecursionR

    10/28/25 8:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

    Salt Lake City, UT, July 29, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the financial markets.Recursion will host a (L)earnings Call on August 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/pEH9b7wv2RxbrFDR7.Ab

    7/29/25 8:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

    SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    11/12/24 4:57:06 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

    SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    11/12/24 10:34:18 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

    SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    11/4/24 4:16:21 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care